- Conditions
- Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms
- Interventions
- CNTO 328; Anti-interleukin-6 monoclonal antibody
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 147
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer
- Interventions
- Bio-Seal Track Plug, No lung plug
- Device · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
- Drug · Device
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
- Conditions
- Chronic Pain
- Interventions
- A-Band (Smart Band-Aid), Empatica Smartwatch, Questionnaires: Hospital Anxiety & Depression Scale, Central Sensitization Inventory, Pain Catastrophizing Scale, Somatic Symptom Scale-8, Pain Self-Efficacy Questionnaire-10, Athens Insomnia Scale
- Device · Combination Product · Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 115 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Bethesda, Maryland
- Conditions
- Anterior Knee Pain Syndrome, Patellofemoral Pain Syndrome
- Interventions
- Dry Needling, Soft Tissue Mobilization, Placebo Control, Hip and core strengthening exercises
- Other
- Lead sponsor
- Mitchell Selhorst
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
- Interventions
- rQNestin, Cyclophosphamide, Stereotactic biopsy
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Chronic Pain, Musculoskeletal Pain, Fibromyalgia, Pain Management
- Interventions
- Electro-Acupuncture (EA), Battle Field Acupuncture (BFA), Wait List Control (WLC)
- Procedure · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Opioid Dependence
- Interventions
- Buprenorphine Extended Release, Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- TAK-881, HYQVIA, SC Investigational Needle Sets
- Biological · Device
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
- Combination Product · Drug
- Lead sponsor
- PolyActiva Pty Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Pyoderma Gangrenosum
- Interventions
- Platelet rich plasma therapy
- Procedure
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
- Interventions
- Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years · Female only
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Anaheim, California • DeLand, Florida • Miami, Florida + 2 more
- Conditions
- Cancer of Pancreas, Pancreatic Neoplasm
- Interventions
- Pancreatic Biopsy, Histological Samples
- Procedure
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Orlando, Florida
- Conditions
- Cirrhosis
- Interventions
- blood draw and muscle biopsy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Mucositis, Pain, Leukemia
- Interventions
- Real Acupuncture, Sham Acupuncture
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lumbar Degenerative Disc Disease
- Interventions
- SB-01 For Injection, Sham Needle
- Drug
- Lead sponsor
- Spine BioPharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Napa, California + 24 more
- Conditions
- Sebaceous Hyperplasia
- Interventions
- Erbium:YAG Laser, Pulsed Dye Laser, Nd:YAG Laser, Electrodessication and curettage
- Device · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pain
- Interventions
- Real acupuncture, Sham acupuncture, VGAIT, VGAIT control
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Lung Cancer (Diagnosis)
- Interventions
- Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Bacterial Infections
- Interventions
- Ciprofloxacin single dose, Ciprofloxacin triple dose
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 497 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Interventions
- filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Seattle, Washington